Legend Biotech CFO Carlos Santos files Form 3

Legend Biotech Corp’s Chief Financial Officer, Carlos E. Santos, has filed an initial Form 3 insider ownership statement.

Accepted by SEC EDGAR 03/18/2026 - 06:52 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Legend Biotech Corp’s Chief Financial Officer, Carlos E. Santos, has filed an initial Form 3 insider ownership statement. The filing identifies him as an officer of the company with the title Chief Financial Officer and does not list any specific transactions in the provided excerpt.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Legend Biotech (LEGN) Form 3 filing by Carlos E. Santos show?

The Form 3 filing shows that Carlos E. Santos is an officer of Legend Biotech, serving as Chief Financial Officer. The excerpt lists no insider transactions, focusing solely on his reporting-person status and role with the company.

Who is the reporting person in the Legend Biotech (LEGN) Form 3?

The reporting person is Carlos E. Santos, identified as an officer of Legend Biotech Corp. He holds the title of Chief Financial Officer, and the filing establishes his status as an insider required to report equity ownership and future transactions.

Does the Legend Biotech (LEGN) Form 3 for Carlos E. Santos report any insider trades?

The provided Form 3 excerpt for Carlos E. Santos shows no reported transactions. Transaction counts for buys, sells, exercises, gifts, tax withholding, and restructurings are all listed as zero, indicating no trading activity in this specific data snapshot.

What insider activity totals are shown in the Legend Biotech (LEGN) Form 3 summary?

The transaction summary shows zero counts and zero shares for buys, sells, exercises, gifts, tax withholding, and restructurings. Net buy-sell shares are listed as zero with a neutral direction, reflecting no activity in the summarized period.

Are any derivative positions disclosed in the Legend Biotech (LEGN) Form 3 for Carlos E. Santos?

The derivative section in the Form 3 excerpt is empty, and the derivative transaction count is zero. This indicates no listed derivative positions or derivative transactions for Carlos E. Santos in the data provided for this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Santos Carlos E

(Last) (First) (Middle)

C/O LEGEND BIOTECH CORP

2101 COTTONTAIL LANE

(Street)

SOMERSET NEW JERSEY 08873

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Legend Biotech Corp [ LEGN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ James Pepin, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)